Published in Biotech Law Weekly, July 6th, 2007
"We are very excited to have dosed the first patient. Following up on the clinical trial kick-off meeting we held in April, we screened approximately 40 patients last week and dosed four patients yesterday," said Carl Pelzel, executive vice president and chief operating officer of Depomed. "Even though there have been several previous trials conducted by other investigators, these trials varied considerably in design, including the doses evaluated. We designed our Phase 2 trial as a PK/PD trial to study the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.